WaveMan
WaveMan · Company
BCAB · Bioatla, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

BCAB BioAtla (BCAB) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001826892
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
5
13F, latest reported quarter

BioAtla insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for BioAtla, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
MCBRINN SYLVIA
Director
BUY
2023-12-26 SEC
4,000
$9.3K
-98.8%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Sep 8, 2023.
  • -11.8% median (-18.1% mean) 90-day return after 6 previous buys.
  • The trade is 26.4% of the 15,125 shares held after it.
  • 3 other insiders bought within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director MCBRINN SYLVIA bought about $9.3K of BCAB on Dec 26, 2023; 3 other insiders bought within 30 days and 5 funds added in the latest 13F quarter.
SHORT JAY M PHD
Chief Executive Officer
BUY
2023-12-20 SEC
50,000
$107.0K
-98.3%
Context
  • 20 earlier Form 4 trades (code P or S) here by this insider (4 buys, 16 sales), the last on Mar 29, 2023.
  • +103.4% median (+106.6% mean) 90-day return after 4 previous buys.
  • The trade is 3.5% of the 1,439,283 shares held after it.
  • 3 other insiders bought within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer SHORT JAY M PHD bought about $107.0K of BCAB on Dec 20, 2023, the largest insider purchase at the company since 2022; 3 other insiders bought within 30 days and 5 funds added in the latest 13F quarter.
STEINMAN LAWRENCE
Director
BUY
2023-12-19 SEC
20,000
$41.0K
-98.1%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Nov 2, 2021.
  • The trade is 52.0% of the 38,459 shares held after it.
  • 3 other insiders bought within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director STEINMAN LAWRENCE bought about $41.0K of BCAB on Dec 19, 2023; 3 other insiders bought within 30 days and 5 funds added in the latest 13F quarter.
Vasquez Christian
See Remarks
BUY
2023-12-19 SEC
7,495
$15.3K
-98.1%
Context
  • 19 earlier Form 4 trades (code P or S) here by this insider (4 buys, 15 sales), the last on Mar 28, 2023.
  • +167.0% median (+138.1% mean) 90-day return after 4 previous buys.
  • The trade is 6.5% of the 115,659 shares held after it.
  • 3 other insiders bought within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Vasquez Christian bought about $15.3K of BCAB on Dec 19, 2023; 3 other insiders bought within 30 days and 5 funds added in the latest 13F quarter.
MCBRINN SYLVIA
Director
BUY
2023-09-13 SECtraded 2023-09-08
2,000
$5.1K
-98.2%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Mar 28, 2023.
  • +11.5% median (-14.7% mean) 90-day return after 5 previous buys.
  • The trade is 18.0% of the 11,125 shares held after it.
  • No other insider bought within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director MCBRINN SYLVIA bought about $5.1K of BCAB on Sep 8, 2023; 5 funds added in the latest 13F quarter.
106 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 101 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
5 funds bought in last quarter
below 95% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
5.4% of the float short (float per yahoo 2026-10-26) · 1.4 days to cover · settled 2026-09-30
below 85% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch BCAB

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-94.2%12M
-97%-36%+25%+86%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns BCAB: institutional holders (13F)

13F holdings, latest reported quarter
ACORN CAPITAL ADVISORS, LLC
108,126 sh
$447.6K
MILLENNIUM MANAGEMENT LLC
70,616 sh
$292.4K
Stonepine Capital Management, LLC
32,864 sh
$136.1K
Lido Advisors, LLC
16,656 sh
$69.0K
GEODE CAPITAL MANAGEMENT, LLC
12,819 sh
$53.1K

Congress trades in BCAB

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

BCAB planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

BCAB mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$24.1K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$37.9K position · as of 2026-06-30
0.0%
State Street Balanced Index Fund
$104 position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$5.7K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$6.3K position · as of 2026-05-31
0.0%
Fidelity Nasdaq Composite Index Fund
$648 position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
1 active
2
Phase 2
0 active
3
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$879.2K
$866.1K
$550.3K
-93%
n/a
2024
$2.0M
$1.2M
$921.4K
-93%
n/a
2023
$3.3M
$154.5K
$1.3M
-70%
n/a
2022
$2.5M
-$3.1M
$1.2M
-58%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 5 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

BCAB financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$23.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
n/a
no debt to cover
Return on equity
n/a
average equity is zero or negative
Return on assets
-171.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
n/a
capital employed is zero or negative
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$59.9M
market value at close 2026-10-26 on 2021-08-13 shares, plus long-term debt only, 2021-12-31 (54 months older than the period end), minus cash 2026-06-30
FCF yield
-38.2%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$59.3M-$73.9M-$129.7M-$108.1M
Net income-$59.6M-$69.8M$123.5M-$106.5M
EPS (diluted)-50.66-71.83-2.58-2.74
Operating cash flow-$48.2M-$71.9M-$104.0M-$90.4M
Cash$7.1M$49.0M$111.5M$215.5M
SEC XBRL, fiscal years, as known on 2026-10-27

BCAB Stock Sonar score 2/7 axes

Find similar shapesCompare
Institutional and government
5
Inputs
  • Funds adding, latest quarter5 · 5 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
43
Inputs
  • Short interest, % of float+5.4% · 57 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+14.9% · 30 pct, sector of 511
5 not measured: Profitability, Financial health, Growth, Insider conviction, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; tax provision or pre-tax income not filed for the four quarters
  • Financial health needs 1 of 2 inputs, 0 present: equity is zero or negative, the ratio has no meaning; no debt to cover
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies